Skip to main content
. Author manuscript; available in PMC: 2020 Oct 15.
Published in final edited form as: Mol Cancer Res. 2019 Nov 1;18(2):216–228. doi: 10.1158/1541-7786.MCR-19-0631

Figure 4.

Figure 4.

CP-DN-ATF5 does not have major effects on expression of CEBPB or CEBPD. A, CP-DN-ATF5 treatment for 24 hours does not significantly affect CEBPB mRNA levels in T98G cells. Values are means ± SEM for 3 independent experiments each carried out in triplicate. B, CP-DN-ATF5 treatment for 48 hours does not significantly affect CEBPB protein levels in T98G cells. Replicate cultures were treated with 0, 50 or 100 μM CP-DN-ATF5 for 48 hours and relative (to ACTIN) levels of CEBPB protein were determined by Western immunoblotting and evaluation of relative band intensities. C, CP-DN-ATF5 treatment for 24 hours has relatively little effect on CEBPD expression in T98G cells as determined by Western immunoblotting. Left panel shows representative blot; right panel, data show quantification of Western immunoblotting in 3 independent experiments. D, CP-DN-ATF5 treatment for 48 hours has relatively little effect on CEBPD expression in T98G cells as determined by Western immunoblotting.